Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Zevalin(Ibritumomab Tiuxetan)+ Rituximab Maintenance

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00582166
First received: December 19, 2007
Last updated: June 2, 2014
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2013
  Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)